Menu Search
Equities

Chugai Pharmaceutical Co Ltd

CUP:FRA

Chugai Pharmaceutical Co Ltd

Actions
  • Price (EUR)36.92
  • Today's Change0.34 / 0.93%
  • Shares traded100.00
  • 1 Year change+26.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

  • Revenue in JPY (TTM)1.14tn
  • Net income in JPY386.96bn
  • Incorporated1943
  • Employees7.60k
  • Location
    Chugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
  • Phone+81 332816611
  • Fax+81 332812828
  • Websitehttps://www.chugai-pharm.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.